Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
13
Ṁ746Jan 1
14%
chance
1D
1W
1M
ALL
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
Get Ṁ1,000 play money
Sort by:
made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl
Related questions
Related questions
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will AOH1996 be FDA approved before 2040?
44% chance
Will aducanumab be withdrawn by the FDA by 2025?
47% chance
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
83% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will there be a recall of Wegovy/Ozempic before 2035?
62% chance